The popularity of Sildenafil initially drove a period of growth for major pharmaceutical companies, however recent changes present a complicated scenario for investors. Lower-cost versions are reducing revenue, and persistent legal battles add more risk to the landscape. While specific companies may still benefit from adjacent offerings, the broade